This was the stock's third consecutive day of gains.
Animal health company Zoetis (NYSE:ZTS) in Q4 CY2024, with sales up 4.7% year on year to $2.32 billion. On the other hand, ...
BTIG lowered the firm’s price target on Zoetis (ZTS) to $200 from $225 and keeps a Buy rating on the shares. The company delivered an in-line ...
Zoetis slightly topped analyst estimates for profitability and met those for revenue in its fourth quarter. But as investors ...
Zoetis received a USDA conditional license for its H5N2 avian flu vaccine for chickens, marking a step in addressing the ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Zoetis exceeded market expectations in Q4 2024, with impressive financial performance despite challenges in specific segments ...
Phibro Animal Health projects strong 2025 revenue growth despite debt concerns. Read this artile to know why I think PAHC ...
In a report released today, Michael Ryskin from Bank of America Securities maintained a Buy rating on Zoetis (ZTS – Research Report). The ...
Shares of Zoetis ( ZTS -6.17%), the leading animal pharmaceutical company, were sliding today after its 2025 guidance came up ...
Q4 2024 Earnings Call Feb 13, 2025, 8:30 a.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback